Eyal Lebel
Impact in
-
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
-
- Chronic Lymphocytic Leukemia Research
Papers in
-
- Amyloidosis: Diagnosis, Treatment, Outcomes 9
- Protein Degradation and Inhibitors 3
- Hematology 15
- Multiple Myeloma Research and Treatments 13
- Co-authors
- Moshe E. Gatt (25 shared papers)Adir Shaulov (11 shared papers)Marjorie Pick (8 shared papers)Shlomit Kfir‐Erenfeld (8 shared papers)Boaz Nachmias (9 shared papers)Polina Stepensky (10 shared papers)Batia Avni (10 shared papers)Miri Assayag (9 shared papers)
In The Last Decade
Eyal Lebel
35 papers receiving 218 citations
Peers
Comparison fields: 5 of 36
- Hematology 54
- Genetics 38
- Oncology 91
- Neurology 37
- Pathology and Forensic Medicine 31
Countries citing papers authored by Eyal Lebel
This map shows the geographic impact of Eyal Lebel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eyal Lebel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eyal Lebel more than expected).
Fields of papers citing papers by Eyal Lebel
This network shows the impact of papers produced by Eyal Lebel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eyal Lebel. The network helps show where Eyal Lebel may publish in the future.
Co-authors
The 25 scholars most cited alongside Eyal Lebel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 23 | |
| 2 | 2022 | 19 | |
| 3 | 2023 | 18 | |
| 4 | 2023 | 18 | |
| 5 | 2023 | 14 | |
| 6 | 2019 | 13 | |
| 7 | 2023 | 12 | |
| 8 | 2022 | 11 | |
| 9 | 2022 | 11 | |
| 10 | 2020 | 10 | |
| 11 | 2019 | 10 | |
| 12 | 2012 | 9 | |
| 13 | 2020 | 9 | |
| 14 | 2023 | 8 | |
| 15 | 2024 | 4 | |
| 16 | 2023 | 3 | |
| 17 | 2024 | 3 | |
| 18 | 2022 | 3 | |
| 19 | 2023 | 3 | |
| 20 | 2022 | 3 |
About Eyal Lebel
Eyal Lebel is a scholar working on Molecular Biology, Hematology, Oncology, Neurology and Pathology and Forensic Medicine, having authored 38 papers that have together received 222 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (13 papers), CNS Lymphoma Diagnosis and Treatment (10 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (9 papers), CAR-T cell therapy research (6 papers), Lymphoma Diagnosis and Treatment (5 papers), Protein Degradation and Inhibitors (3 papers), Peptidase Inhibition and Analysis (3 papers) and Drug Transport and Resistance Mechanisms (2 papers). The work is most often cited by research in Hematology (54 citations), Genetics (38 citations), Oncology (91 citations), Neurology (37 citations) and Pathology and Forensic Medicine (31 citations). Eyal Lebel has collaborated with scholars based in Israel, Italy and Canada. Frequent co-authors include Moshe E. Gatt, Adir Shaulov, Marjorie Pick, Shlomit Kfir‐Erenfeld, Boaz Nachmias, Polina Stepensky, Batia Avni, Miri Assayag, Irit Avivi and Sigal Grisariu. Their work appears in journals such as Blood, Cancers, British Journal of Haematology, Journal of Clinical Medicine and Acta Haematologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.